Navigation Links
In troubled economic times, BioSquare 2009 successfully serves as business and innovation starter
Date:3/30/2009

Lyon, France, March 30, 2009 / b3c newswire / - The 2009 edition of the BioSquare business conference was held March 9-11 in Lyon. For three days, the 343 companies in attendance, including 11 big pharma companies, held some 2,500 business meetings. The conference created real dynamics in a difficult economic context by offering biotech and pharma company managers a solid chance to develop business opportunities, create partnerships and get acquainted with new technologies in booming biotech industries.

BioSquare 2009 geared to the biotech market and companies 

“For Biotech companies, the financing of innovation is essential, which may be quite a challenge in the current economic climate. Finding the right partners will be an even more critical factor of success. In just three days, BioSquare 2009 served as a place for business exchanges leading to international partnerships,” said Bernadette Guagliata, BioSquare’s CEO.
In order to maintain any kind of leadership in innovation during these difficult times, it is necessary to convince investors, to communicate knowledge and know-how effectively, to determine which sectors are most favourable in terms of growth, to set up strategic partnerships, and to know how to sign the right contract… By enabling biotech companies to get advice from renown experts in these key areas, through its thematic sessions, BioSquare has positioned itself as an event with high added value.
“With the ability to create synergies among the various technologies (high-tech, cleantech, biotech), to present young biotech companies, to cross-match information...BioSquare becomes a relevant business conference,” states Albin Jourda, CEO of Gallium Moore, a merger/acquisition consulting firm specialised in information technology, biotech and cleantech.

BioSquare 2009 sets up meetings, partnerships and businesses 

With more than 2,500 business meetings, the 343 biotech firms represented by more than 520 delegates turned BioSquare into an effective business and trade platform. 
On Tuesday alone, 11 pharmaceutical leaders including Johnson&Johnson, GSK, Bayer, Sanofi-Aventis and 20 Biotech companies including Ipsogen, Theregen, Biomay, Ascendis pharma– had the chance to expose their know-how and R&D programmes, with the evidence that their technologies need others to exist, grow and find the right market.
Gilles Rubinstenn, Managing Director of the Pierre-Gilles de Gennes Foundation, notes: “We got involved in preparing the thematic programme for BioSquare 2009 and we were especially satisfied with the return on this investment: The Foundation’s main objective is to bring the academic research sector together with innovative firms to set up projects with high added value. During these three days, 40 face-to-face meetings with biotech companies left us with 25 serious partnership prospects.”

BioSquare 2009 talks innovations and new applications for Biotech technologies  

For the 2009 edition’s scientific and strategic programme, BioSquare decided to give the floor to booming innovative industries like cleantech, stem cells and theranostics.
Regarding the workshop on theranostics, Marc Essodaigui, Vice President Marketing & Sales, Europe & Asia at Ipsogen, notes: “Theranostics as a concept has been around a long time but is coming into real applications now. A better understanding of diseases allows more targeted therapies; and these need increasingly high-performance diagnostic tools. The pharma industry and the biotechs are therefore working together, especially on cancer, where patient monitoring is essential and diagnostic tools have real benefit.” In the current economic situation, “The biotechs that have innovative diagnostic technologies have more of a trump card to play, especially in supporting pharma activity for clinical development,” he concludes.

BioSquare in 2010 

While fewer delegates attended the 2009 edition, activity remains strong. BioSquare 2009 shows that the biotechs are standing up to the crisis. “The continuous progress and discoveries in the field of biotechnology area - more than ever – opening new opportunities for Health, Agriculture, Energy-management and Pollution-control” As Bernadette Guagliata noted at the opening session, “This makes BioSquare even more important, because we can effectively and efficiently be a support, to optimise and stimulate the process of partnering and networking at an international level.”
BioSquare 2010 edition will be held in Switzerland in an entirely overhauled format for more effectiveness, more contacts and more deals...

Press contact

Frédéric Le Gall 
fred@tamaco.fr 
+33 (0)6 64 28 89 00

BioSquare Contact

Bernadette Guagliata
bernadette.guagliata@bioevents.eu


'/>"/>
b3c newswire

Related biology news :

1. Hatchery fish outnumber wild chinook salmon in troubled fall run
2. Shark attacks decline worldwide in midst of economic recession
3. Capillary mats labor-saving, economical alternative to hand watering
4. Basic research critical to Americas economic recovery
5. Study says middle class coral reef fish feel the economic squeeze
6. First-ever socioeconomic study on coral reefs points to challenges of coastal resource management
7. Top scientific meeting urges coordinated response to economic and environmental crises
8. New studies find global warming will have significant economic impacts on Florida coasts
9. Economic value of insect pollination worldwide estimated at 153 billion euros
10. Book breaks new ground in the study of economics and forest threats management
11. Scripps study sets high economic value on threatened Mexican mangroves
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives ... the award for Excellence in Volunteer Experience from US2020. , US2020’s mission is ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... ... a four-tiered line of medical marijuana products targeting the needs of consumers who ... packaging of Kindred takes place in Phoenix, Arizona. , As operators of two ...
Breaking Biology Technology: